Urology Area Networks ( UANs ) should be established to improve patient outcomes and experience . By aligning our objectives to deliver MTFM technologies with GIRFT and organisations including the South Yorkshire Acute Federation and West Yorkshire Association of Acute Trusts , we are contributing to the development of UANs in our region . This collaborative approach helps to provide urology services over a close geographical footprint , alleviate pressures on frontline staff , facilitate resource sharing , and improves the management of waiting times .
Importantly , the UAN offer should empower patients to have more say over where and when they receive surgical treatment . We have been working with our developing UANs to ensure patients have access to all these effective MTFM Benign Prostatic Enlargement treatments within the service network to meet patient and system needs .
We have seen progress on adoption and early impacts of XprESS and Thopaz + which provide alternative treatments to more invasive procedures .
To date , three providers in our region have adopted XprESS , enabling chronic sinusitis procedures to be performed out of theatre and into outpatients under local anaesthetic . This has generated cost savings of approximately £ 1,400 per patient , bringing faster patient recovery and reduced discharge times .
Early adopters of Thopaz +, a portable digital system for managing chest drains , have seen improvements in patient safety and clinical effectiveness . Benefits include faster patient recovery , reduced length of stay in hospital and improved clinical decision making to diagnose patients , through the continuous monitoring of air leaks and fluid loss .
“
We have had a number of quality successes due to this partnership . It has been a great experience for me working alongside extra support ( Health Innovation Yorkshire &
Humber ) who can bridge certain gaps and stakeholders that possibly I wouldn ’ t normally have contact with .”
Lynn Taylor Smith , Account Manager , Medela ( suppliers of Thopaz +)
Impact of Benign Prostatic Enlargement treatments between April 2022 and March 2024 :
5,299 patients benefitted saving the NHS
c . £ 1.36m
15 Transforming Lives Through Innovation